FDA Confirms Dexamethasone Safe for Ongoing Generic Approvals
Published Date: 5/6/2026
Notice
Summary
The FDA has decided that Dexamethasone Elixir, 0.5 mg/5 mL, wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, keeping options open for patients and pharmacies. No changes in costs or availability are expected, so everyone can breathe easy!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA Finds Dexamethasone Not Withdrawn
On May 6, 2026, FDA determined that DEXAMETHASONE (dexamethasone) elixir, 0.5 mg/5 mL, was not withdrawn from sale for reasons of safety or effectiveness. FDA reviewed the files and relevant postmarketing data and found no information indicating the product was withdrawn for safety or effectiveness.
Generic Approvals Can Continue
Because FDA concluded the listed DEXAMETHASONE elixir was not withdrawn for safety or effectiveness, FDA will not begin procedures to withdraw approval of approved ANDAs that refer to this product and may continue to approve new ANDAs that refer to it so long as they meet legal and regulatory requirements. The listed product is ANDA 088254, originally approved July 27, 1983.
Possible Labeling Updates for ANDAs
FDA stated that if it determines labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. The product was reported discontinued by Wockhardt Bio AG in a November 16, 2021 letter and a citizen petition was submitted February 4, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-08936 — Public Meeting of the National Volcano Early Warning and Monitoring System Advisory Committee
The National Volcano Early Warning and Monitoring System Advisory Committee is holding a public meeting on June 3-4, 2026, to discuss how to keep people safe from volcanoes. This meeting affects communities near volcanoes, scientists, and policymakers by shaping better volcano monitoring and warning plans. Anyone interested can join in person or online, but you need to register by May 30, 2026.
Next: 2026-08940 — Information Collection; Addressing DEI Discrimination by Federal Contractors
Federal contractors will soon need to share info showing they’re fighting discrimination based on diversity, equity, and inclusion (DEI). Four big agencies—DoD, GSA, NASA, and OFPP—are asking for public feedback on this new info collection by July 6, 2026. This effort aims to keep workplaces fair without adding too much paperwork or cost.